Myelodysplastic Syndromes
Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
Melissa BadamoMyelodysplastic Syndromes | April 16, 2024
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
View More
Leah SherwoodMyelodysplastic Syndromes | March 28, 2024
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
Leah SherwoodMyelodysplastic Syndromes | March 25, 2024
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
Melissa BadamoAcute Myeloid Leukemia | March 21, 2024
A significant number of patients receiving ivosidenib had reduced levels of voriconazole and posaconazole.
Melissa BadamoMyelodysplastic Syndromes | March 22, 2024
The case study included four patients with CMML who had KRAS mutations and a multitude of autoimmune diseases.
Douglas Tremblay, MDMyelodysplastic Syndromes | March 15, 2024
The study also explored the role of this combination in transitioning patients to HSCT.
Advertisement
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | March 14, 2024
An FDA committee voted that the benefits of imetelstat outweigh the risks for the treatment of anemia in lower-risk MDS.
Melissa BadamoAcute Myeloid Leukemia | April 1, 2024
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | February 27, 2024
The CHMP of the European Medicines Agency recommended approval of luspatercept for transfusion-dependent anemia due to MDS.
Blood Cancer TalksAcute Myeloid Leukemia | March 4, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | February 8, 2024
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Melissa BadamoAcute Myeloid Leukemia | February 8, 2024
Oral decitabine plus cedazuridine is a safe and effective alternative to intravenous decitabine.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | February 14, 2024
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Melissa BadamoMyelodysplastic Syndromes | February 2, 2024
Complete response was achieved in 14 patients (22%) in the sabatolimab group, versus 11 patients (18%) in the placebo group.
Hana Safah, MDVideo Insights | January 24, 2024
The panel shares their outlook for the future of MDS research and treatment.
Hana Safah, MDVideo Insights | December 19, 2023
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
Hana Safah, MDVideo Insights | December 19, 2023
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
Hana Safah, MDVideo Insights | December 19, 2023
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Hana Safah, MDVideo Insights | February 8, 2024
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
Advertisement
Advertisement
Editorial Board